VISTAGEN THERAPEUTICS INC (VTGN)

US92840H4002 - Common Stock

4.7  +0.03 (+0.64%)

After market: 4.59 -0.11 (-2.34%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
1.09M1.11M
1.83%		-230K
-120.72%		1.082M
570.43%
EBITDA
YoY % growth
-17.81M
13.96%		-47.63M
-167.43%		-59.14M
-24.17%		N/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
-17.93M
13.80%		-47.78M
-166.48%		-59.27M
-24.05%		-33.004M
44.32%
Operating Margin
-1,644.95%-4,304.50%25,769.57%-3,050.29%
EPS
YoY % growth
-0.39
22.00%		-2.86
-633.33%		-8.65
-202.45%		-1.63
81.16%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-0.37
78.87%
Revenue
Q2Q % growth		206.805K
14.89%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-10.915M
10.83%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth		 -0.22
85.33%		-0.310.0928.70%
Q2 2024
Q2Q % growth		 -0.66
72.50%		-0.690.034.84%
Q4 2023
Q2Q % growth		 -1.75
35.19%		-1.53-0.22-14.38%
Q3 2023
Q2Q % growth		 -1.50
-2,900.00%		-2.140.6429.97%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth		 411.4K
128.56%		555.39K-143.99K-25.93%
Q2 2024
Q2Q % growth		 280K
131.46%		181.56K98.44K54.22%
Q1 2024
Q2Q % growth		 180K
-41.94%		188.7K-8.7K-4.61%
Q4 2023
Q2Q % growth		 180K
350.00%		180K∞%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 15.7% 0% 15.03%
Revenue0% N/A 0% -13.58%